Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health Inc. (OTCQB: ODYY) is a medical company focused on life-saving and life-enhancing medical solutions, and its news flow reflects this emphasis on critical care and diagnostic technologies. Company announcements highlight development milestones, licensing transactions, financing arrangements and strategic asset sales that shape its evolving portfolio.
Recent news has detailed Odyssey’s entry into the breast cancer diagnostics marketplace through a Master Technology and Sub-license Agreement for exclusive, worldwide rights to BreastCheck ae, a non-invasive test for breast abnormalities. Press releases describe BreastCheck ae as a home-use, temperature-based screening tool that provides results in about 15 minutes and is intended to complement established diagnostic procedures. Updates also cover regulatory status, including FDA registration in the United States and registrations with authorities in the European Union and the United Kingdom.
Odyssey’s news archive also covers progress on its Save A Life choking rescue device, a patented vacuum-based system designed to dislodge airway obstructions rapidly. The company has reported creating a prototype and planning further development with the goal of an FDA submission, illustrating how it communicates development stages and regulatory intentions to investors and stakeholders.
Another key theme in Odyssey’s news is corporate and financial strategy. Releases describe the sale of its neurological drug technology pipeline, including the concussion candidate ONP-002, to Oragenics, Inc., as well as the resulting investment in Oragenics preferred stock. Additional coverage explains long-term service contracts and financing facilities, such as the multi-year maintenance service agreement and related funding capacity with Mast Hill Fund, L.P., which the company characterizes as supporting its transition toward recurring revenue and commercialization initiatives.
Investors and observers can use the ODYY news page on Stock Titan to follow these developments, including device development updates, licensing agreements, regulatory steps, financing transactions and portfolio changes that may influence Odyssey Health’s business trajectory.
Summary not available.
Summary not available.
Summary not available.
Odyssey Health, Inc. (OTC: ODYY) has announced the launch of a concept phase for an intra-nasal antidote targeting organophosphate nerve agents, a significant global threat. The innovative device aims to deliver medication directly to the brain through the olfactory nerve, potentially providing immediate protection against nerve gas exposure. Unlike traditional auto-injectors, the new delivery method is designed to minimize pain and risk of infection, offering faster and more effective treatment. With increasing concerns about chemical warfare, particularly in conflict zones like Ukraine, this development addresses a critical need for accessible and effective medical solutions.
Odyssey Health, Inc. (OTC: ODYY) provided a company update, emphasizing progress in developing life-enhancing medical products. The highlight is a successful Phase I clinical trial for a concussion drug, with preparations for Phase II underway. The global concussion treatment market, valued at $6.9 billion in 2020, is expected to grow to $8.9 billion by 2027. Odyssey also announced plans for a nerve agent antidote, a choking rescue device, and a rapid EKG tool, while raising over $5 million and reducing share dilution.
Odyssey Health, Inc. (OTC: ODYY) provides a significant update on its concussion drug development program, which addresses a global medical need. Since acquiring the drug's rights in March 2021, the company has made notable advancements, including:
- Completion of a Phase I clinical trial proving safety and tolerability.
- Development of a novel breath-propelled intranasal delivery device.
- Raised over $5 million to support ongoing efforts and secured access to an equity line of up to $10 million.
Odyssey aims to transform concussion treatment with its synthetic neurosteroid.
Odyssey Health, Inc. (OTC: ODYY) will hold its Annual Meeting of Stockholders on January 12, 2023. To participate, stockholder proposals must be submitted by November 25, 2022, to the corporate offices in Las Vegas. The proposals should comply with company bylaws. Odyssey is focused on developing unique medical products and solutions with significant market potential. The company emphasizes creating and acquiring distinct assets and technologies that enhance clinical utility.
Odyssey Health, Inc. (OTC: ODYY) is strengthening its commitment to Odyssey NeuroPharma with key executive appointments, including Erik Emerson as Chief Commercial Officer and Greg Gironda as Chief Operating Officer. Both executives bring over 50 years of combined experience in the pharmaceutical sector. Odyssey NeuroPharma aims to address unmet medical needs in traumatic brain injury, planning a Phase II clinical trial to evaluate treatment efficacy. Currently, no FDA-approved treatments exist for concussions, which affect over 5 million people in the U.S. annually.
Odyssey Health, Inc. (OTC: ODYY) has filed for patent protection for its innovative intranasal brain-drug delivery device, designed to treat concussions. The recently completed Phase I study confirmed the safety and effectiveness of using this device with Odyssey's concussion drug, PRV-002, on 40 healthy volunteers. The study observed no device failures, indicating strong performance. This technology aims to enhance drug delivery for central nervous system conditions, potentially leading to significant market opportunities in the healthcare sector.
Odyssey Health (OTC: ODYY) has launched Odyssey Neuropharma, its new subsidiary dedicated to developing drugs targeting neurological disorders. The company aims to overcome the blood-brain barrier with an innovative intranasal delivery device, improving drug efficiency and reducing side effects. Planned products include treatments for concussion, Niemann-Pick type C disease, and a nerve agent antidote. Previous studies highlight the promising efficacy of the intranasal method, suggesting targeted brain delivery with minimal systemic absorption.